 |
|
|
| |
Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis
|
| |
| |
Reported by Jules Levin
DDW 2015 May 16-19 Wash DC
Hézode C,1 Herring Jr R,2 Pockros P,3 Sheikh A,4 JM Vierling,5 Lee S,6 Thompson A,7 Bhore R,8 Hughes EA,8 Swenson ES,9 Yin PD9
1CHU Henri Mondor, Université Paris-Est, Créteil, France; 2Quality Medical Research, Nashville, TN, USA; 3Scripps Clinic, La Jolla, CA, USA; 4Gastrointestinal Specialists of Georgia, Marietta, GA, USA; 5Baylor College of Medicine, Houston, TX, USA;
6University of Calgary, Calgary, AB, Canada; 7St. Vincent's Hospital and the University of Melbourne, Melbourne, Victoria, Australia; 8Bristol-Myers Squibb, Princeton, NJ, USA; 9Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
